Financial Statements for the 2nd quarter of fiscal year ending March 31, 2019 (From Apr. 1, 2018 to Sep. 30, 2018) Summary of consolidated results

Transcription

1 Financial Statements for the 2nd quarter of fiscal year ending March 31, 2019 (From Apr. 1, to Sep. 30, ) Summary of consolidated results JMS Co., Ltd. Company Code No November 8, 1

2 Highlights in Business Results Results Previous Forecast Results Diff. Year-over- Year Diff. from forecast Net sales 27,402 28,700 28,426 1, % (1.0%) Operating profit % 40.2% Ordinary profit % 32.0% attributable to owners of parent % 42.1% Basic earnings per share JPY 8.65 JPY JPY Exchange Rate (average during period) US Dollar Euro (unit: JPY) Singapore Dollar ,64 in sales and profit for the 2nd Quarter of FYE Mar Japan Overseas - sales of New Hemodialysis Machine GC-X01 and Dysphagia related products - sales of AV Fistula Needle -The influence of increased sales and the decrease of selling cost, resulted in operating profit -The addition of share of profit of entities accounted for using equity method, resulted in ordinary profit Dividend forecast -Interim dividend: JPY 8 per share We have conducted a share consolidation of common stock of JMS Co., Ltd. pursuant to which two (2) shares were consolidated into one (1) share effective as of October 1,. Accordingly, the Net income per share has been calculated assuming that such share consolidation has been conducted at the beginning of the previous fiscal year. 2

3 20,115 18, Summary by segment (geographical area) Japan Singapore * China 20,822 19, incl. internal transaction for third party - 3.5% 71.3% 9,372 9,427 4,668 4, incl. internal transaction for third party - 0.6% Decreased 14.2% 1, , (3) incl. internal transaction for third party - Decreased 12.8% Decreased by 39 million yen [] sales of New Hemodialysis Machine GC-X01 and Dysphagia related products raised net sales. [Ordinary profit] The influence of increase sales and the decrease of selling cost resulted in profit. [] sales of Safety Scalp Vein Needles for North America market raised net sales. [Ordinary profit] The influence of increased labor cost resulted in profit. *This segment includes Indonesia local subsidiary. [] Decreased sales of Infusion Sets for Japan market by production transfer to Philippines reduced net sales. [Ordinary profit] The influence of decreased sales resulted in loss. 3

4 Summary by segment (geographical area) Philippines Others * 747 incl. internal transaction - 3,724 3,921 for third party - ~Product introduction~ % 5.3% (307) (214) Improved by 93 million yen % Apr. Sep. [] sales of Infusion Sets for Japan market raised net sales. [Ordinary profit] The influence of increased sales reduced in loss. *This segment includes business activity of domestic subsidiaries, Germany, United States and South Korea. Hemodialysis Machines Hemodialysis machine is a device for pulling blood from a patient into an extracorporeal circuit. The blood is purified by a dialyzer and returned to the patient by the hemodialysis machine. 4

5 by Business Segment Apr. Sep. Apr. Sep. 11,195 11,719 Transfusion 16.4% Others 2.7% 8,399 9,223 Cardiovascular 7.3% Apr. Sep. Infusion & Nutrition 41.2% Dialysis 32.4% 4,807 4,649 2,286 2, Infusion & Nutrition Dialysis Cardiovascular Transfusion Others 5

6 increase or decrease (Customer's Location) Europe 8.4% North America 11.2% Asia 12.6% Apr. Sep. Others 1.8% Japan 66.0% (121) (143) 28,426 27,402 JPY 1,023 million Japan Asia North America Europe Others 6

7 Selling, General and Admin. Expenses 6,796 6, % 23.6% Diff. Year -over- Year Labor Cost 2,896 2, % Transport % R & D % Depreciation (7) (4.7%) Others 2,232 2,025 (207) (9.3%) Total 6,796 6,710 (86) (1.3%) [R & D] Clinical trial expense for the development of a new product increased. [Others] commission decreased. 7

8 Ordinary profit : Compared with the previous year Minus factor Plus factor Increase of Gross JPY 259 million 108 (35) Decrease of SGA Decrease of Non-operating profit 30 Impact of Exchange rate 593 The underlined figures exclude impact of exchange rate. 8

9 Forecast for FYE Mar FYE Mar. Result FYE Mar Forecast Year-over-Year Net sales 56,520 58, % Operating profit 573 1, % Ordinary profit 820 1, % attributable to owners of parent % Basic earnings per share JPY JPY Exchange Rate (average during period) US Dollar Euro (unit: JPY) Singapore Dollar

10 Topics Announcement date -Announcement of finished the production of Ono Plant. Sep. 26, -Announcement of disposition of treasury shares as the stock compensation plan with transfer restrictions Jul. 18, -Announcement of introduction of the stock compensation plan with transfer restrictions May. 18, -Launching new product TWIN SHIELD, Catheter connection system Apr. 18, TWIN SHIELD 10

11 The Bridge to Good Health Care The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures. 11